Introduction {#sec1}
============

Alzheimer's disease (AD) is a neurodegenerative and psychiatric disorder. AD has become the most devastating disease worldwide, and its prevalence is expected to greatly increase over the next few decades as the population ages.^[@ref1]^ The hallmarks of AD are cognitive deficit and memory impairments, which are caused by the massive loss of neurons and synapses.^[@ref2]^ Accumulating evidence suggests that abnormally folded β-amyloid (Aβ) protein can be one of the important pathological contributors to neuronal loss in AD.^[@ref3]−[@ref5]^ Aβ plaques can result in oxidative stress, inflammation, and neurotoxicity, all of which can initiate the pathogenic cascade and ultimately lead to cognitive dysfunction.^[@ref6]−[@ref8]^ Thus, the strategy to increase the Aβ clearance is being actively pursued as a promising disease-modifying therapy. Currently, five drugs have been approved for the treatment of AD. Four of them are acetylcholinesterase inhibitors (donepezil, tacrine, rivastigmine, and galantamine) and one *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor antagonist (memantine).^[@ref9]^ Donepezil is usually considered as the first choice for AD patients' treatment.^[@ref10]^ However, donepezil can only improve the cognition and behavior of the patients with AD but does not have any effect on slowing the progression or curing the disease.^[@ref11]^ Besides, donepezil has many side effects, including loss of appetite, diarrhea, gastrointestinal upset, difficulty sleeping, vomiting, and muscle cramping, which further limits its application.^[@ref12]^

Recently, the studies on active ingredients from natural products and medicinal herbs for treating AD have attracted substantial attention.^[@ref13]−[@ref15]^ α-Mangostin (α-M, [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}) is a natural xanthone separated from the mangosteen pericarp.^[@ref16]^ α-M has been reported to possess a wide spectrum of biological activities such as anti-inflammatory, cardioprotective, antitumor, antidiabetic, antibacterial, antifungal, antioxidant, antiparasitic, and antiobesity activities.^[@ref17]−[@ref26]^ Recent evidence further suggests that α-M can inhibit amyloid aggregation.^[@ref27]^ However, the major obstacles facing the application of α-M are due to its cytotoxic activities, hydrophobic nature, and thus low bioavailability and accumulation in the target organs. To decrease its cytotoxicity and improve the neuroprotective effect, we modified the structure of α-M through the medicinal chemistry approach. The initial substrate α-M was converted into the cyclized compound AMG ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Then, the hydroxyl at C-2 in AMG was reacted with different isocyanates to afford a series of α-M carbamate derivatives.

![Reagents and Conditions: (a) CH~3~I or C~2~H~5~Br, K~2~CO~3~, Reflux, and 12 h; (b) DDQ, Toluene, 40 °C, and 5 h; (c) BTC, Et~3~N, DMAP, DCM, rt, and 10 h](ao0c00057_0010){#sch1}

Hence, one of the aims of our present work is to elucidate AChE inhibitory and neuroprotective effects of AMG derivatives *in vitro*. As a result, **AMG-1**, after structural optimization, has improved neuroprotective effects. To further investigate whether **AMG-1** can improve the learning and memory of AD's model of rats, we also induced an AD-like rat model by injecting Aβ~25-35~ into the bilateral hippocampus of rats. At the same time, the molecular mechanism that underlies the experimental observations was further analyzed by computational systems pharmacology.^[@ref28]^ Our study showed that **AMG-1** not only protected rat cerebral hippocampal neurons against Aβ~25-35~ oligomer-induced β-amyloid deposition but also improved the learning and memory ability and alleviated neuronal injury by scavenging β-amyloid in the hippocampus of AD model rats.

Results {#sec2}
=======

Synthesis of AMG Derivatives {#sec2.1}
----------------------------

The preparation of the target compounds started from α-M through four steps as described in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. The prenyl group is an important factor for the retention of cytotoxicity in prenylated xanthones,^[@ref29]^ so α-M was cyclized to yield AMG (**4**) to reduce cytotoxicity. The methylation of substituted aniline (**1a**--**1r**) resulted in substituted *N*-methylaniline (**2a**--**2r**) and *N*-ethylaniline (**3**). The carbamoyl group has been proven to be an important pharmacophore of acetylcholinesterase inhibitory activity.^[@ref30],[@ref31]^ Furthermore, carbamates could also affect the expression and processing of the Aβ-precursor protein, one of the most important therapeutic goals in Alzheimer's disease.^[@ref32]^ To improve the bioactivity of α-M, the carbamoyl groups were then introduced into AMG (**4**) by reacting with chlorides (**3a**--**3r**) to afford α-M carbamate derivatives **AMG-1**--**AMG-16**.

*In Vitro* Experiments {#sec2.2}
----------------------

Sixteen derivatives of AMG were evaluated for AChE inhibition by an *in vitro* assay based on a microplate. The IC~50~ values for AChE inhibition are summarized in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. A majority of the derivatives showed potent capacity to inhibit AChE activity, with IC~50~ values lying in the micromolar range, which demonstrates an important role of the α-M moiety in the AChE inhibition of the developed α-M carbamate group. The neuroprotective activity of target compounds was evaluated on the neuronal-like PC12 cells damaged by H~2~O~2~. The results expressed as EC~50~ are shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, and most of the α-M derivatives showed better protective effects than the positive control drug edaravone (EC~50~ = 69.98 ± 5.73 μM) on injured PC12 cells. The EC~50~ of α-M was tested to be more than 100 μM. Among the AMG derivatives, **AMG-1** exhibited the most potent neuroprotective activity, with EC~50~ values of 1.61 ± 0.35 μM. The cytotoxicity was compared between α-M and derivatives in PC12 cells. The results showed that the inhibition ratio of cell proliferation decreased from 73.1 to 45.3% after the cyclization of α-M to AMG ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Notably, **AMG-1**, which was then selected for the *in vivo* studies on the rat model of AD, has an inhibition ratio of 7.2%.

###### 50% Inhibitory Concentration (IC~50~) of Derivatives against AChE and 50% Effective Concentration EC~50~ on PC12 Cells[d](#t1fn4){ref-type="table-fn"}

  compound      IC~50~ (μM)[a](#t1fn1){ref-type="table-fn"}   EC~50~ (μM)[b](#t1fn2){ref-type="table-fn"}   compound   IC~50~ (μM)[a](#t1fn1){ref-type="table-fn"}   EC~50~ (μM)[b](#t1fn2){ref-type="table-fn"}
  ------------- --------------------------------------------- --------------------------------------------- ---------- --------------------------------------------- ---------------------------------------------
  galantamine   4.24 ± 1.65                                   ND[c](#t1fn3){ref-type="table-fn"}            AMG-7      43.45 ± 5.27                                  \>100
  α-M           34.28 ± 6.06                                  \>100                                         AMG-8      \>100                                         \>100
  AMG           41.21 ± 6.28                                  \>100                                         AMG-9      45.97 ± 15.32                                 \>100
  edaravone     ND[c](#t1fn3){ref-type="table-fn"}            69.98 ± 5.73                                  AMG-10     47.78 ± 16.78                                 13.07 ± 2.25
  AMG-1         52.55 ± 11.27                                 1.61 ± 0.35                                   AMG-11     43.60 ± 12.33                                 12.33 ± 4.65
  AMG-2         35.14 ± 9.38                                  12.77 ± 4.23                                  AMG-12     19.20 ± 6.87                                  \>100
  AMG-3         32.89 ± 7.78                                  13.36 ± 5.17                                  AMG-13     15.07 ± 3.56                                  \>100
  AMG-4         \>100                                         8.27 ± 2.01                                   AMG-14     40.64 ± 13.78                                 \>100
  AMG-5         \>100                                         \>100                                         AMG-15     34.46 ± 9.38                                  \>100
  AMG-6         \>100                                         \>100                                         AMG-16     37.49 ± 11.24                                 \>100

Mean ± standard error of the mean (SEM) of three experiments for 50% inhibition of AChE.

Mean ± SEM of three independent experiments for 50% antioxidant neuroprotective effect.

Not determined.

Inhibitory activity (IC~50~, μM) of AChE and neuroprotective effective concentration (EC~50~, μM) for the studied compounds, galantamine and edaravone.

###### Cytotoxic Effects of α-M and Derivatives in PC12 Cells

  compounds (10 μM)   inhibition ratio (%)   compounds (10 μM)   inhibition ratio (%)
  ------------------- ---------------------- ------------------- ----------------------
  edaravone           0                      AMG-8               0
  α-M                 73.1                   AMG-9               0
  AMG                 45.3                   AMG-10              0
  AMG-1               7.2                    AMG-11              0
  AMG-2               6.7                    AMG-12              0
  AMG-3               5.9                    AMG-13              3.1
  AMG-4               0                      AMG-14              5.3
  AMG-5               7.8                    AMG-15              5.2
  AMG-6               7.4                    AMG-16              0
  AMG-7               0                                           

*In Vivo* Experiments {#sec2.3}
---------------------

### Acute Toxicity {#sec2.3.1}

During the acute oral toxicity experiment period, the mice were found to have messy furs and loose gray stool around the anus. Except for the 1310 mg/kg group, death could be found in other groups ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). Particularly, the mice in the highest dosed group (4000 mg/kg) were found dead within 16--48 h after administration. For the 14 day observation, most mice had a recovery. LD~50~ values and their 95% confidence intervals of **AMG-1** in mice were calculated according to the improved Bliss method. The results indicated that the LD~50~ values of **AMG-1** in mice were 2.47 g/kg and the 95% confidence intervals were between 2.13 and 2.89 g/kg. Results showed that **AMG-1** had no obvious toxicity at the level of 20 mg/kg or less as the dose for administration in the following studies.

###### Results of the Acute Oral Toxicity Test of AMG-1 in Mice

  group     number of rats   dosage (mg/kg)   deaths   death rate (%)
  --------- ---------------- ---------------- -------- ----------------
  control   10                                0        0
  1         10               4000             9        90
  2         10               3200             7        70
  3         10               2560             6        60
  4         10               2048             4        40
  5         10               1638             1        10
  6         10               1310             0        0

### Animal Behavior Tests in the Open Field and Morris Water Maze {#sec2.3.2}

The one-way ANOVA analysis of locomotor activity and distance traveled in the open field showed the treatment effects of **AMG-1** on AD rats. The total distance moved by the Aβ model group was the shortest among the six groups ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A), and the Aβ model group spent the least time in the central zone ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B), indicating the low ability of space exploration in the Aβ model group on average. However, both the **AMG-1** (20 mg/kg)-treated group and the donepezil group showed a significant increase compared to the Aβ model group (*p* \< 0.05, *p* \< 0.01) in the total distance moved (28.55 ± 6.87, 31.37 ± 7.14, vs 17.34 ± 3.88, respectively). **AMG-1**-treated groups showed a significant (*p* \< 0.05--0.01) and dose-dependent increase in the time spent in the central zone compared to the Aβ model group (*p* \< 0.01).

![Effect of **AMG-1** administration on behaviors related to locomotor activity and the improvement of spatial cognition in AD rats. (A) Total distance moved and (B) time spent in the central zone in the OFT. (C) Effect of **AMG-1** on escape latency, (D) total distance moved, and (E) number of crossings in the MWM. (Values are expressed as mean ± SEM and were analyzed using the *t*-test. \#*P* \< 0.05, \#\#*P* \< 0.01 compared with the sham group and \**P* \< 0.05 \*\**P* \< 0.01 compared with the Aβ model group in each figure).](ao0c00057_0001){#fig1}

To examine whether the ability of spatial learning and memory was significantly improved by administering **AMG-1** in AD rats, we adopted a commonly utilized Morris water maze test for evaluation. The results exhibited that in the training trials on the first day, all rats explored the objects equally ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A, *p* \> 0.05). During the retention phase, the escape latency ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C) and the total distance traveled ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}D) of the rats in the Aβ-induced model group were significantly increased compared to the rats in the sham control group (*p* \< 0.01), while **AMG-1**-treated rats showed significant improvements compared to the model rats (*p* \< 0.05). In the probe trial ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}E), the platform was removed. **AMG-1** treatment not only promoted learning during the training trials but also improved memory retention during the probe trials. Rats in **AMG-1** treatment groups spent significantly less time to reach the place of the removed platform and spent significantly more time in the target quadrant, compared to the model rats (*p* \< 0.05). Thus, these results demonstrate that **AMG-1** treatment can improve the memory loss in Aβ-induced rats.

### Neuroprotective Effects of AMG-1 Revealed by Brain Tissue Staining {#sec2.3.3}

Hematoxylin and Eosin (HE) staining was performed to detect the pyramidal cells of the hippocampus CA3 region and the neurohistopathological changes in the brain sections in rats in different groups under a light microscope (200×). The representative morphologic pictures of neuronal cells of the rats from HE staining are illustrated in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}. [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A shows no remarkable neuronal abnormalities in the hippocampus CA3 region of rats in the sham control group. The pyramidal cells of the CA3 region are arranged neatly and tightly, and no cell loss can be found. Cells are round and intact with nuclei stained clearly in dark blue (red arrows in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A). However, obvious hippocampal histopathological damage is observed in the model group. The pyramidal layered structure is disintegrated, and neuronal loss can be found in the CA3 region. Pyramidal neurons with pyknotic nuclei and a shrunken or irregular shape can also be observed ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). These abnormalities were attenuated by **AMG-1** treatment. The pyramidal cells in the **AMG-1** (5, 10, and 20 mg/kg) groups have better cell morphology and density than those in the model group ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D--F).

![HE staining of the neuronal cells of the hippocampus CA3 region. Hematoxylin and eosin staining of the hippocampus CA3 region. The red arrows indicate the histologic changes (×200). (A) Sham group, (B) Aβ model group, and (C) donepezil group. (D--F) **AMG-1** (5, 10, and 20 mg/kg) + the model group, respectively.](ao0c00057_0002){#fig2}

In the hippocampal CA1 and CA3 areas, representative Nissl-stained neurons can be observed in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}. Intact cells can be found in sham-operated animals as well as all unaffected regions following AD. The results from the Nissl staining showed that in the hippocampal CA1 area of AD rats, the cells were sparsely distributed and the number of cells with eumorphism was significantly reduced. Based on the results, Aβ significantly increased necrotic death in the hippocampal CA1 region of the rats in the Aβ model group, compared with the rats in the sham group ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A,B). However, with the **AMG-1** treatment, neuronal damage was significantly attenuated in rats in 10 and 20 mg/kg groups, which suggested that **AMG-1** can significantly prevent the neuronal loss in Aβ-induced AD rats ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}E--G).

![Nissl staining of the hippocampal CA1 region after induction of Aβ. Damaged cells (*n* = 5 rats per group, three sections per rat) were sparsely arranged, and their shapes were fuzzy (the red arrows indicate the necrotic cells). (A) Sham group, (B) Aβ model group, (C) donepezil group, and (D--F) **AMG-1** (5, 10, and 20 mg/kg) + model group, respectively. The results are shown as mean ± SED. (G) Quantitative analysis of the necrotic cell count.](ao0c00057_0003){#fig3}

To evaluate the effects of **AMG-1** on the AD rat model, neurofibrillary tangle pathology was observed by modified Bielschowsky silver staining. The notable dark neurofibrillary tangles (red arrows in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}) that characterize the neuronal damage in the hippocampus can be found for rats in the Aβ~25--35~-treated group ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B--F). The damaged neurons can rarely be found in the hippocampus for rats in the sham group ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). A large amount of dark staining of neurons and senile plaques can be frequently observed in the hippocampus for rats in the AD model group ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B). Meanwhile, the number of senile plaques for rats in the **AMG-1** treatment (10, 20 mg/kg) groups was less ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}E,F). Our data demonstrate that amyloid exposure can induce senile plaque deposition. Furthermore, the results suggest that **AMG-1** can reduce the senile plaques and repair the neuron injury for the AD model rats.

![Silver staining. Administration of **AMG-1** to animals for 30 days (D--F) in comparison to (C) donepezil, (B) model, and (A) sham rats.](ao0c00057_0004){#fig4}

### AMG-1 Treatment Decreases Aβ~1-42~ in the Hippocampus of the AD Rat Brain {#sec2.3.4}

Quantification of immunohistochemical staining for Aβ~1-42~ showed that there are significantly more positive-stained neurons for rats in the model group (*p* \< 0.01) than in the sham group ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A,B). Compared with the model group, the **AMG-1** treatment groups (10, 20 mg/kg) showed a significantly reduced expression of Aβ~1-42~ (*p* \< 0.05) ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}E--G). Red arrows show areas of Aβ~1-42~-positive amyloid plaques.

![Effect of AMG-1 on Aβ1-42 expression in the hippocampal CA1 region. (A) Sham rat group, (B) Aβ model group, (C) donepezil treatment group, and (D--F) **AMG-1** treatment rat groups (5, 10, 20 mg/kg/day) (*n* = 4, four sections per rat). (G) Quantification of the immunohistochemistry of Aβ plaque numbers in the hippocampus (*n* = 4, four sections per rat).](ao0c00057_0005){#fig5}

### Chemogenomics Knowledgebase Network Analysis {#sec2.3.5}

In the observation of experimental evidence, **AMG-1** remarkably reversed behavioral deficits and significantly improved cognitive functions in AD model rats. The results suggest that the neuroprotective effects of **AMG-1** are realized through scavenging β-amyloid in the hippocampus. To (1) better understand the complex interaction of the compound and the corresponding targets and (2) establish a comprehensive understanding of the therapeutic mechanisms, the chemogenomics knowledgebase was adapted for network analysis.

Chemogenomics databases for Alzheimer's disease, drug abuse research, and cardiovascular disease, as well as two chemogenomics tools, TragetHunter and HTDocking, were combined for retrieving the information for protein targets as detailed in the [Materials and Methods](#sec4){ref-type="other"} section. The compound-target network was first constructed ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). In total, 55 nodes of protein targets were connected with α-mangostin and AMG through 68 edges ([Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}). A total of 33 protein targets were predicted to have an association with α-mangostin, while 35 protein targets were predicted to interact with **AMG-1**. Thirteen nodes were shared between the two compounds. The annulation and the substitution of two hydroxyl groups changed the size and the physical--chemical properties of α-mangostin. As a result, distinctive targets can be observed between these two compounds. The reported targets for α-mangostin were recurred and marked in green. The effect of **AMG-1** on preventing Tau hyperphosphorylation was proposed through the experiments and marked in yellow.

![Chemogenomics-based target mapping for α-mangostin and AMG-1. Pink nodes represent the purely predicted targets. Yellow nodes represent the experimentally validated targets. Green nodes represent the known targets. Known or experimentally validated targets are connected with the corresponding target through solid edges. Predicted targets are connected through dashed edges.](ao0c00057_0006){#fig6}

###### Protein Annotation for the Predicted Targets[a](#t4fn1){ref-type="table-fn"}

  protein                                                                                                           docking score   gene name   compound
  ----------------------------------------------------------------------------------------------------------------- --------------- ----------- -------------
  cytochrome P450 1B1 (CP1B1_HUMAN)                                                                                 11.7            CP1B1       α-mangostin
  pyruvate kinase isozymes M1/M2 (KPYM_HUMAN)                                                                       11.6            KPYM        α-mangostin
  amine oxidase \[flavin-containing\] B, Monoamine oxidase type B, MAO-B                                            11.0            MAO-B       α-mangostin
  lanosterol synthase (ERG7_HUMAN)                                                                                  10.9            ERG7        α-mangostin
  acetylcholinesterase, AChE                                                                                        10.9            ACHE        α-mangostin
  cAMP-specific 3′,5′-cyclic phosphodiesterase 4B (PDE4B_HUMAN)                                                     10.8            PDE4B       α-mangostin
  cAMP-specific 3′,5′-cyclic phosphodiesterase 4D (PDE4D_HUMAN)                                                     10.7            PDE4D       α-mangostin
  prostaglandin G/H synthase 2, Cyclooxygenase-2, COX-2                                                             10.7            COX-2       α-mangostin
  tryptophan 5-hydroxylase 1 (TPH1_HUMAN)                                                                           10.6            TPH1        α-mangostin
  aldo-keto reductase family 1 member C2 (AK1C2_HUMAN)                                                              10.5            AK1C2       α-mangostin
  cGMP-specific 3′,5′-cyclic phosphodiesterase (PDE5A_HUMAN)                                                        10.5            PDE5A       α-mangostin
  medium-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADM_HUMAN)                                         10.3            ACADM       α-mangostin
  proto-oncogene tyrosine-protein kinase Src (SRC_HUMAN)                                                            10.3            SRC         α-mangostin
  nitric oxide synthase, inducible; NOS type II; NOS2                                                               10.3            NOS2        α-mangostin
  cyclooxygenase                                                                                                    10.3            COX-1       α-mangostin
  T-cell surface glycoprotein CD1d (CD1D_HUMAN)                                                                     10.2            CD1D        α-mangostin
  dual specificity protein kinase CLK1 (CLK1_HUMAN)                                                                 10.2            CLK1        α-mangostin
  serine/threonine-protein kinase haspin (HASP_HUMAN)                                                               10.2            HASP        α-mangostin
  catalase (CATA_HUMAN)                                                                                             10.1            CATA        α-mangostin
  catalase (CATA_HUMAN)                                                                                             10.1            CATA        α-mangostin
  carnitine O-acetyltransferase (CACP_HUMAN)                                                                        10.1            CRAT        α-mangostin
  cAMP and cAMP-inhibited cGMP 3′,5′-cyclic phosphodiesterase 10A (PDE10_HUMAN)                                     10.1            PDE10       α-mangostin
  pirin (PIR_HUMAN)                                                                                                 10.1            PIR         α-mangostin
  liver carboxylesterase 1; Brain carboxylesterase hBr1; CES1                                                       9.9             CES1        α-mangostin
  cyclooxygenase                                                                                                    9.7             COX-2       α-mangostin
  cyclin-dependent kinase 5; Cell division protein kinase 5; CDK5                                                   9.6             CDK5        α-mangostin
  sphingomyelin phosphodiesterase 2; SMPD2                                                                          9.4             SMPD2       α-mangostin
  matrix metalloproteinase-16 (MMP16_HUMAN)                                                                         9.3             MMP16       α-mangostin
  matrix metalloproteinase-9 (MMP9_HUMAN)                                                                           9.3             MMP9        α-mangostin
  E3 ubiquitin-protein ligase Mdm2 (MDM2_HUMAN)                                                                     7.9             MDM2        α-mangostin
  apoptosis regulator Bcl-2 (BCL2_HUMAN)                                                                            7.6             BCL2        α-mangostin
  G1/S-specific cyclin-D3\@Cell division protein kinase 4(CCND3_HUMAN/CDK4_HUMAN)                                   7.0             CDK4        α-mangostin
  fatty acid synthase (FAS_HUMAN)                                                                                   6.7             FAS         α-mangostin
  induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1_HUMAN)                                          5.7             MCL1        α-mangostin
  acetylcholinesterase, AChE                                                                                        12.3            ACHE        AMG-1
  cholinesterase, Butyrylcholine esterase, BCHE                                                                     12.3            BCHE        AMG-1
  nitric oxide synthase, brain; Neuronal NOS; NOS type I; NOS1                                                      12.2            NOS1        AMG-1
  peptidyl-prolyl cis-trans isomerase FKBP1A (FKB1A_HUMAN)                                                          12.1            FKB1A       AMG-1
  aldo-keto reductase family 1 member C3 (AK1C3_HUMAN)                                                              12.0            AK1C3       AMG-1
  T-cell surface glycoprotein CD1d (CD1D_HUMAN)                                                                     11.9            CD1D        AMG-1
  T-cell surface glycoprotein CD1a (CD1A_HUMAN)                                                                     11.8            CD1A        AMG-1
  NAD(P)H dehydrogenase \[quinone\] 1 (NQO1_HUMAN)                                                                  11.8            NQO1        AMG-1
  collagen type IV α-3-binding protein (C43BP_HUMAN)                                                                11.7            C43BP       AMG-1
  prostaglandin reductase 2 (PTGR2_HUMAN)                                                                           11.7            PTGR2       AMG-1
  cytochrome P450 1B1 (CP1B1_HUMAN)                                                                                 11.5            CP1B1       AMG-1
  advanced glycosylation end product-specific receptor (RAGE_HUMAN)                                                 11.4            RAGE        AMG-1
  calcitonin gene-related peptide type 1 receptor, Receptor activity-modifying protein 1(CALRL_HUMAN/RAMP1_HUMAN)   11.3            CALRL       AMG-1
  serine/threonine-protein kinase Pim-2 (PIM2_HUMAN)                                                                11.2            PIM2        AMG-1
  cholesteryl ester transfer protein (CETP_HUMAN)                                                                   11.2            CETP        AMG-1
  cyclin-dependent kinase 5; Cell division protein kinase 5; CDK5                                                   11.1            CDK5        AMG-1
  glycogen synthase kinase-3 β, GSK3 β, GSK3B                                                                       10.6            GSK3 β      AMG-1
  amine oxidase \[flavin-containing\] B, Monoamine oxidase type B, MAO-B                                            10.6            MAO-B       AMG-1
  β-secretase 1, Aspartyl protease 2, BACE1                                                                         10.5            BACE1       AMG-1
  high-affinity cGMP-specific 3′,5′-cyclic phosphodiesterase 9A, PDE9A                                              10.3            PDE9A       AMG-1
  3-hydroxy-3-methylglutaryl-coenzyme A reductase; HMG-CoA reductase; HMGCR                                         10.2            HMGCR       AMG-1
  α-synuclein (Tau)                                                                                                 10.2            SNCA        AMG-1
  steroid 5 α-reductase 1                                                                                           10.1            SRD5A1      AMG-1
  prostaglandin G/H synthase 2, Cyclooxygenase-2, COX-2                                                             10.0            COX-2       AMG-1
  adenosine A2a receptor                                                                                            10.0            A2a         AMG-1
  cyclooxygenase                                                                                                    9.9             COX-1       AMG-1
  amyloid β A4 protein                                                                                              9.7             A β A4      AMG-1
  collagenase 3 (MMP13_HUMAN)                                                                                       9.5             MMP13       AMG-1
  neutrophil collagenase (MMP8_HUMAN)                                                                               9.3             MMP8        AMG-1
  E3 ubiquitin-protein ligase Mdm2 (MDM2_HUMAN)                                                                     8.9             MDM2        AMG-1
  G1/S-specific cyclin-D3\@Cell division protein kinase 4 (CCND3_HUMAN/CDK4_HUMAN)                                  8.3             CDK4        AMG-1
  apoptosis regulator Bcl-2 (BCL2_HUMAN)                                                                            8.1             BCL2        AMG-1
  fatty acid synthase (FAS_HUMAN)                                                                                   8.0             FAS         AMG-1
  arachidonate 12-lipoxygenase                                                                                      7.8             ALOX12      AMG-1
  induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1_HUMAN)                                          5.7             MCL1        AMG-1

The docking score represents the predicted −logKd.

The analysis of signaling pathways ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}) was followed to connect the protein targets with both physiological and pathological processes. Targets were identified to be involved in a total of 37 nodes of pathways through 94 edges. The complexity of the network reflects the polypharmacology feature of α-mangostin and its derivative, **AMG-1**, which is consistent with the broad therapeutic spectrum of these compounds. Pathways connected with more than three targets were placed in the center and colored in orange for emphasis. Among the highly shared pathways, signaling in cholinergic neurons, cholesterol and sphingolipid transport and biosynthesis, and tau pathology can have a direct or indirect association with AD. Oxidative phosphorylation, neuroprotective action of lithium, etc. can also have influences on the pathology of AD. The effect of **AMG-1** on treating diseases can be in a one-molecule, multiple-targets manner.

![Target-pathway network. Blue nodes represent the targets for α-mangostin and **AMG-1** identified through the target mapping. Yellow and orange nodes represent signaling pathways or processes. In particular, orange nodes are shared by three or more targets and placed in the center for emphasis.](ao0c00057_0007){#fig7}

The target-pathway network bridged the gap between the targets and the specific diseases. The target-disease network ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}) was constructed afterward. A total of 25 nodes of diseases were connected with targets through 125 edges. Most diseases can be categorized into four groups: neurological, cancer-related, cardiovascular, and inflammatory diseases. The reported effects of α-mangostin on treating cancers, benefiting cardiovascular disorders, and improving cognitive functions can be recurred or verified in the target-disease network. Limited reports can be found to associate α-mangostin and neurological disorders, except AD. However, the potential of α-mangostin and **AMG-1** for treating other neurological disorders, including depression, Parkinson's disease, and Huntington's disease, can be investigated. One explanation that the identified diseases are mainly neurological and cardiovascular is that the chemogenomics knowledgebase we used focuses on AD, drug abuse, and the cardiovascular system. It is a shortcoming that using focused knowledgebases can have a limited target coverage. However, on the other hand, using focused knowledgebases according to reported compound activities can better develop a systematic understanding of the specific areas, especially for the AD research in this case.

![Target-disease network. Blue nodes represent the targets for α-mangostin and **AMG-1** identified through the target mapping. Salmon nodes represent different diseases. Diseases are categorized into four categories, neurological, cancer-related, cardiovascular, and inflammatory. Diseases are connected with categories with edges in the corresponding color.](ao0c00057_0008){#fig8}

For the node of AD, 18 edges were connected to a variety of protein targets. An AD-specific target-disease network of α-mangostin and **AMG-1** was then constructed ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}). Seven nodes of targets were connected with α-mangostin, and 15 nodes of targets were connected with **AMG-1**, while four targets were shared between these two compounds. Seventeen nodes of targets (except TPH1) were categorized into five groups: β-amyloid (Aβ) deposit, deficits of acetylcholine, tau hyperphosphorylation, oxidative stress, and lipid metabolism, according to their association in pathology hypothesis regarding AD. Among these five groups, lipid metabolism may attract relatively less attention. Besides having been reported to be associated with Aβ deposit and tau hyperphosphorylation, lipid metabolism can also have a direct or unclear effect on AD pathology, including (1) biosynthesis of neuroprotective allopregnalolone, (2) regulation of cholesteryl ester transformation, and (3) interference in the metabolism of sphingomyelin. The distinctions in predicted targets for α-mangostin and **AMG-1** reflected the alteration in physical--chemical properties caused by the annulation and the substitution on two hydroxyl groups of α-mangostin. The experimentally observed inhibition of tau hyperphosphorylation from straining can be caused directly by interacting SNCA and indirectly by interfering GSK3β. In addition, the prevention of Aβ deposit can be the result of the interaction of BACE1, CDK5, and HMGCR. Also, **AMG-1** can inherit the ability of α-mangostin to inhibit cholinesterases, which further benefits the AD treatment. Further investigation can be conducted toward NQO1 and CETP. In response to the increased oxidatives, NADPH quinone oxidoreductase (NQO1) can be activated. The reduced HDL level can be observed in AD, which can be a result of regulating the cholesteryl ester transfer protein (CETP). The regulation in lipid metabolism and oxidative stress can contribute to the therapeutic potential of **AMG-1**. The finding supports the hypothesis that **AMG-1** demonstrates its therapeutic effects in a one-molecule, multiple-targets manner.

![AD-specific target-disease network. Pink nodes represent the purely predicted targets. Yellow nodes represent the experimentally validated targets. Green nodes represent the known targets. Targets are categorized into five AD pathology hypothesis groups, lipid metabolism, tau hyperphosphorylation, β-amyloid deposit, deficits of acetylcholine, and oxidative stress, with edges in the corresponding color.](ao0c00057_0009){#fig9}

*In Silico* Property Prediction {#sec2.4}
-------------------------------

The experimental results clearly show the neuroprotective effects of **AMG-1**. Given that the targeting site for treating AD is in the central nervous system, it is critical to evaluate the ability of a compound to pass the blood--brain barrier (BBB). Eight combinations of fingerprints and algorithms were calculated ([Table [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"}) for both α-mangostin and AMG-1 as specified in [Materials and Methods](#sec4){ref-type="other"}. The lipophilicity was increased for **AMG-1** (*c* log *P* = 7.83) after the annulation and the substitution of two hydroxyl groups of α-mangostin (*c* log *P* = 6.07). Although the combination of SVM with different fingerprint types can result in contradictory predictions, the algorithm AdaBoost provided consistent results that **AMG-1** can have a better chance to cross the BBB. The differences among the abilities for these two compounds to pass the BBB help explaining the distinctive neuroprotective effects to some extent. Both the compounds passed the pan-assay interference compounds (PAINS)-Remover, indicating that there are no undesired substructural features. The toxic hazard estimation using Toxtree suggested no improved toxicity profile of **AMG-1**. Both compounds were estimated to have their toxic hazard high. The chemical modification should be considered to decrease the toxicity while maintaining or increasing the activity to move further.

###### BBB Permeability Prediction

  algorithms and fingerprints    threshold   α-mangostin   AMG-1
  ------------------------------ ----------- ------------- ---------
  SVM and MACCS                  0.02        --0.046       --0.094
  SVM and Openbabel (FP2)        0           0.146         0.155
  SVM and Molprint 2D            0           0.341         0.681
  SVM and PubChem                0           --0.070       --0.135
  AdaBoost and MACCS             0           --4.006       --0.070
  AdaBoost and Openbabel (FP2)   0           8.623         9.675
  AdaBoost and Molprint 2D       0           --1.614       3.049
  AdaBoost and PubChem           0           0.089         1.226

Discussion {#sec3}
==========

For this work, the study began with the natural product, α-mangostin. **AMG-1** was designed and synthesized as a derivative for α-M in an effort to reduce the toxicity and increase the lipophilicity. Notably, the cyclization significantly reduced the toxicity of α-M, while the improved neuroprotective activities after the cyclization can also be observed at the cell level. Animal behavior studies using an open-field test and a Morris water maze showed that **AMG-1** treatment can improve the memory loss and cognitive function in Aβ-induced rats. After the sacrifice of the animals, multiple staining methods, including HE staining, Nissl staining, and Bielschowsky silver staining, were applied to brain slices for mechanism studies. The **AMG-1** treatment can (1) have neuron cells with better morphology and density compared with the disease model, (2) significantly prevent the neuronal loss in Aβ-induced AD rats, and (3) reduce the senile plaque and repair the neuron injury in the AD model. The quantification of immunohistochemical staining further demonstrated that the **AMG-1** treatment significantly reduced the expression of Aβ~1-42~. A computational systems pharmacology analysis using the chemogenomics knowledgebase was applied for network studies. Compound-target, target-pathway, and target-disease networks were constructed, integrating both *in silico* analysis and reported experimental data. The systematic network analysis (1) confirmed the broad therapeutic spectrum of α-mangostin, (2) bridged the corresponding targets with specific pathways and diseases, and (3) speculated that **AMG-1** can demonstrate its therapeutic effects in a one-molecule, multiple-targets manner. In a nutshell, **AMG-1** is reported here to be a promising compound with the potential for future modification and development for the study of Alzheimer's disease.

Materials and Methods {#sec4}
=====================

All chemicals, reagents, and solvents were purchased from commercial suppliers and used without further purification unless otherwise noted. Isolation and reactions were monitored by analytical thin-layer chromatography (TLC) on silica gel 60 F254 percolated plates with a fluorescent indicator (purchased from Qingdao Haiyang Inc.). Visualization on TLC was achieved by UV light (254 or 365 nm) and a typical TLC indicator solution (10% sulfuric acid/ethanol solution). Column chromatography was performed on silica gel (200--300 mesh) for the purification of intermediates and final compounds. ^1^H NMR and ^13^C NMR spectra were recorded on a Bruker Avance (500 MHz) spectrometer at 300 K in CD~3~COCD~3~ or CDCl~3~ with tetramethylsilane (TMS) as an internal standard. Chemical shifts are reported in ppm (δ); coupling constants (*J*) are given in hertz; and peak multiplicities are reported as singlet (s), doublet (d), triplet (t), and multiplet (m). The electrospray ionization mass spectrometry (ESI-MS) and high-resolution ESI-MS data were recorded on an Agilent-6210-LC/TOF mass spectrometer. All final compounds were more than 95% pure, which was analyzed by a high-performance liquid chromatography (HPLC) system (Waters Corporation, Milford, MA). α-Mangostin was isolated from the pericarp of *G. mangostana*, as reported in the literature.^[@ref33]^

General Procedures for the Synthesis and Spectral Data of the Synthesized Compounds {#sec4.1}
-----------------------------------------------------------------------------------

### General Procedure for the Synthesis of **2a**--**2r** and **3** {#sec4.1.1}

To a solution of compound **1** (0.01 mmol) and K~2~CO~3~ (0.012 mmol) in acetone, CH~3~I or C~2~H~5~Br (0.011 mmol) was added dropwise. The reaction mixture was heated to reflux for 12 h. Then, the mixture was filtrated and the filtrate was concentrated to afford the crude product. The crude product was chromatographed on silica gel (petroleum ether (PE)/EtOAc = 40:1, v/v) to give compounds **2** and **3** as colorless oils (isolated yield 80.0--91.2%).

### Synthesis of **AMG** (**4**) {#sec4.1.2}

To a solution of α-M (4.0 mmol) in toluene, 2, 3-dicyano-5, 6-dichlorobenzoquinone (DDQ) (8.0 mmol) was added at ice bath conditions and stirred at 40 °C for 5 h. The reaction mixture was evaporated to remove toluene. Then, the crude product was purified by silica gel chromatography (PE/EtOAc = 10:1) to afford **3** (isolated yield 85.0%).

### General Procedure for the Synthesis of **AMG-1--AMG-16** {#sec4.1.3}

BTC (0.20 mmol) was added to 10 mL of anhydrous CH~2~Cl~2~. A solution of **2** or **3** (0.20 mmol) and Et~3~N (0.18 mmol) in 5 mL of anhydrous CH~2~Cl~2~ was added dropwise to the above mixture at ice bath conditions and stirred at room temperature for another 4 h. Then, a solution of AMG or BMG (0.1 mol) and 4-dimethylaminopyridine (DMAP, catalytic amount) in 5 mL of anhydrous CH~2~Cl~2~ was added dropwise to the above mixture at ice bath conditions. After a 6 h reaction at room temperature, the reaction mixture was diluted with H~2~O and extracted with EtOAc. The organic layers were then combined and washed with brine and dried over anhydrous Na~2~SO~4~. The solution was evaporated to afford the crude product. Then, the crude product was purified by silica gel column chromatography (PE/EtOAc = 20:1) to give **AMG-1**--**AMG-16** as a yellow solid (isolation yield 70.0--85.0%).

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl methyl(phenyl)carbamate (**AMG-1**) {#sec4.1.4}

^1^H NMR (CDCl~3~ 500 MHz): δ 13.55 (1H, *s*, 5-OH), 7.46--7.40 (4H, m, Ar-H), 7.32 (1H, t, 7.8 Hz, Ar-H), 7.28 (1H, s, H-1), 6.74 (1H, d, *J* = 10.2 Hz, H-9), 6.26 (1H, s, H-8), 5.59 (1H, d, *J* = 10.1 Hz, H-10), 5.20 (1H, brs, H-15), 4.12 (2H, d, *J* = 4.0 Hz, H-14), 3.46 (3H, s, OCH~3~), 3.39 (3H, s, N-CH~3~), 1.83 (3H, s, H~3~-18), 1.68 (3H, s, H~3~-17), 1.48 (6H, s, H~3~-12 and H~3~-13). ^13^C NMR: δ 182.2, 160.3, 158.0, 156.4, 153.8, 152.4, 149.5, 146.7, 142.5, 138.5, 131.9, 130.9, 129.6, 129.3, 127.2, 123.1, 116.3, 115.6, 110.4, 104.5, 104.0, 94.2, 78.1, 61.6, 38.6, 28.4, 28.4, 26.3, 25.8, 19.2. ESI-MS *m*/*z* (%): 540 \[M -- H\]^−^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl ethyl(phenyl)carbamate (**AMG-2**) {#sec4.1.5}

^1^H NMR (CD~3~COCD~3~ 500 MHz): δ 13.55 (1H, s, 5-OH), 7.45--7.36 (5H, m, Ar-H), 7.38 (1H, s, H-1), 6.70 (1H, d, *J* = 10.1 Hz, H-9), 6.29 (1H, s, H-8), 5.74 (1H, d, *J* = 10.1 Hz, H-10), 5.22 (1H, br*s*, H-15), 4.10 (2H, d, *J* = 5.0 Hz, H-14), 3.86 (3H, s, OCH~3~), 3.60 (2H, q, *J* = 8.0 Hz, N-CH~2~), 1.81 (3H, s, H~3~-18), 1.65 (3H, *s*, H~3~-17), 1.48 (6H, s, H~3~-12 and H~3~-13), 1.08 (3H, *t*, *J* = 8.0 Hz). ^13^C NMR: δ 182.3, 160.3, 157.8, 156.1, 153.9, 152.1, 150.1, 146.8, 141.1, 138.4, 130.9, 129.3, 128.3, 127.7, 126.6, 123.2, 115.6, 110.4, 104.6, 104.1, 94.2, 78.0, 61.5, 52.7, 46.2, 28.4, 28.4, 26.4, 25.6, 18.2, 12.8. ESI-MS *m*/*z* (%): 556 \[M + H\]^+^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl methyl(*o*-tolyl)carbamate (**AMG-3**) {#sec4.1.6}

^1^H NMR (CDCl~3~ 500 MHz): δ 13.55 (1H, s, 5-OH), 7.32--7.27 (4H, m, Ar-H), 7.28 (1H, s, H-1), 6.74 (1H, d, *J* = 10.0 Hz, H-9), 6.26 (1H, s, H-8), 5.58 (1H, d, *J* = 10.0 Hz, H-10), 5.17 (1H, t, *J* = 5.5 Hz, H-15), 4.12 (2H, d, *J* = 5.5 Hz, H-14), 3.36 (3H, s, OCH~3~), 3.35 (3H, s, N-CH~3~), 2.11 (3H, s, Ar-CH~3~) 1.81 (3H, s, H~3~-18), 1.66 (3H, s, H~3~-17), 1.48 (6H, s, H~3~-12 and H~3~-13). ^13^C NMR: δ 183.4, 161.5, 159.0, 157.5, 154.7, 152.0, 151.3, 146.6, 139.0, 132.1, 131.1, 129.0, 128.8, 127.4, 127.2, 126.4, 123.1, 121.4, 116.1, 115.6, 110.1, 104.5, 104.0, 94.1, 78.1, 61.3, 38.8, 28.4, 28.4, 27.0, 26.0, 21.1, 18.2. ESI-MS *m*/*z*: 554 \[M -- H\]^−^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-ylmethyl(*m*-tolyl)carbamate (**AMG-4**) {#sec4.1.7}

^1^H NMR (CD~3~COCD~3~ 500 MHz): δ 13.63 (1H, s, 5-OH), 7.47--7.31 (4H, m, Ar-H), 7.38 (1H, s, H-1), 6.70 (1H, d, *J* = 10.0 Hz, H-9), 6.31 (1H, s, H-8), 5.73 (1H, d, *J* = 10.0 Hz, H-10), 5.26 (1H, t, *J* = 5.5 Hz, H-15), 4.17 (2H, d, *J* = 5.5 Hz, H-14), 3.16 (3H, s, OCH~3~), 2.83 (3H, s, N-CH~3~), 2.07 (3H, s, Ar-CH~3~), 1.83 (3H, s, H~3~-18), 1.67 (3H, s, H~3~-17), 1.49 (6H, s, H~3~-12 and H~3~-13). ^13^C NMR: δ 183.4, 161.6, 159.0, 157.6, 154.8, 152.4, 148.1, 146.7, 142.4, 139.2, 138.4, 132.1, 129.8, 129.0, 127.1, 123.2, 123.2, 116.2, 115.9, 115.6, 111.9, 105.1, 104.7, 95.0, 79.2, 62.2, 38.6, 28.4, 28.4, 26.3, 25.8, 21.3, 18.2. ESI-MS *m*/*z*: 556 \[M + H\]^+^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-ylmethyl(*p*-tolyl)carbamate (**AMG-5**) {#sec4.1.8}

^1^H NMR (CDCl~3~ 500 MHz): δ 13.55 (1H, s, 5-OH), 7.29 (2H, d, *J* = 8.0 Hz, Ar-H), 7.28 (1H, s, H-1), 7.22 (2H, d, *J* = 8.0 Hz, Ar-H), 6.74 (1H, d, *J* = 10.0 Hz, H-9), 6.26 (1H, s, H-8), 5.73 (1H, d, *J* = 10.0 Hz, H-10), 5.25 (1H, brs, H-15), 4.17 (2H, d, *J* = 3.5 Hz, H-14), 3.19 (3H, s, OCH~3~), 3.11 (3H, s, N-CH~3~), 2.38 (3H, s, Ar-CH~3~), 1.83 (3H, s, H~3~-18), 1.67 (3H, s, H~3~-17), 1.48 (6H, s, H~3~-12 and H~3~-13). ^13^C NMR: δ 177.4, 157.7, 156.2, 152.8, 152.7, 152.6, 149.6, 148.0, 146.6, 138.4, 131.9, 129.9, 129.8, 126.3, 123.6, 118.7, 116.2, 111.9, 110.9, 110.2, 110.0, 99.6, 77.6, 62.4, 38.6, 28.3, 28.3, 26.1, 25.8, 21.0, 18.1. ESI-MS *m*/*z* (%): 556 \[M + H\]^+^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl(2-methoxyphenyl)(methyl)carbamate (**AMG-6**) {#sec4.1.9}

^1^H NMR (CDCl~3~ 500 MHz): δ 13.55 (1H, s, 5-OH), 7.34 (2H, m, Ar-H), 7.28 (1H, s, H-1), 7.00 (2H, m, Ar-H), 6.74 (1H, d, *J* = 10.0 Hz, H-9), 6.26 (1H, s, H-8), 5.68 (1H, d, *J* = 10.0 Hz, H-10), 5.17 (1H, t, *J* = 5.5 Hz, H-15), 4.06 (2H, d, *J* = 5.5 Hz, H-14), 3.92 (3H, s, OCH~3~), 3.49 (3H, s, OCH~3~), 3.42 (3H, s, N-CH~3~), 1.83 (3H, s, H~3~-18), 1.66 (3H, s, H~3~-17), 1.47 (6H, s, H~3~-12 and H~3~-13). ^13^C NMR: δ 182.3, 160.2, 158.0, 156.4, 155.1, 153.2, 153.0, 149.8, 146.6, 138.2, 131.8, 131.0, 129.2, 128.8, 127.1, 123.0, 120.8, 115.9, 115.6, 111.8, 110.1, 104.5, 104.0, 94.1, 78.0, 61.2, 55.6, 37.7, 28.4, 28.4, 26.3, 25.8, 18.1. ESI-MS *m*/*z*: 572 \[M + H\]^+^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl(3-methoxyphenyl)(methyl)carbamate (**AMG-7**) {#sec4.1.10}

^1^H NMR (CDCl~3~ 500 MHz): δ 13.55 (1H, s, 5-OH), 7.35--7.25 (2H, m, Ar-H), 7.28 (1H, s, H-1), 7.02--6.87 (2H, m, Ar-H), 6.74 (1H, d, *J* = 10.0 Hz, H-9), 6.26 (1H, s, H-8), 5.68 (1H, d, *J* = 10.0 Hz, H-10), 5.16 (1H, brs, H-15), 4.11 (2H, d, *J* = 3.5 Hz, H-14), 3.84 (3H, s, OCH~3~), 3.49 (3H, s, OCH~3~), 3.45 (3H, s, N-CH~3~), 1.83 (3H, s, H~3~-18), 1.63 (3H, s, H~3~-17), 1.49 (6H, s, H~3~-12 and H~3~-13). ^13^C NMR: δ 182.2, 160.3, 160.2, 158.0, 156.4, 153.8, 152.4, 149.5, 146.7, 143.6, 138.5, 131.9, 129.9, 127.3, 127.2, 123.2, 123.1, 116.3, 115.6, 112.6, 110.5, 104.5, 104.0, 94.2, 78.1, 61.2, 55.5, 38.6, 28.4, 28.4, 26.4, 25.8, 18.2. ESI-MS *m*/*z*: 572 \[M + H\]^+^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl(4-methoxyphenyl)(methyl)carbamate (**AMG-8**) {#sec4.1.11}

^1^H NMR (CDCl~3~ 500 MHz): δ 13.55 (1H, s, 5-OH), 7.32 (2H, d, *J* = 8.0 Hz, Ar-H), 7.27 (1H, s, H-1), 6.94 (2H, d, *J* = 8.0 Hz, Ar-H), 6.74 (1H, d, *J* = 10.0 Hz, H-9), 6.26 (1H, s, H-8), 5.58 (1H, d, *J* = 10.0 Hz, H-10), 5.18 (1H, brs, H-15), 4.11 (2H, d, *J* = 3.5 Hz, H-14), 3.83 (3H, s, OCH~3~), 3.48 (3H, s, OCH~3~), 3.38 (3H, s, N-CH~3~), 1.82 (3H, s, H~3~-18), 1.67 (3H, s, H~3~-17), 1.48 (6H, s, H~3~-12 and H~3~-13). ^13^C NMR: δ 182.2, 160.2, 159.7, 158.0, 156.4, 153.8, 152.7, 149.5, 146.7, 138.4, 131.9, 127.7, 127.2, 123.2, 123.1, 116.2, 115.6, 114.5, 110.5, 104.5, 104.0, 94.1, 78.1, 61.6, 55.5, 38.9, 28.4, 28.4, 26.3, 25.8, 18.2. ESI-MS *m*/*z* (%): 570 \[M -- H\]^−^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl(3-ethylphenyl)(methyl)carbamate (**AMG-9**) {#sec4.1.12}

^1^H NMR (CD~3~COCD~3~ 500 MHz): δ 13.55 (1H, *s*, 5-OH), 7.35--7.14 (4H, m, Ar-H), 7.26 (1H, s, H-1), 6.73 (1H, *d*, *J* = 10.0 Hz, H-9), 6.25 (1H, s, H-8), 5.58 (1H, d, *J* = 10.0 Hz, H-10), 5.20 (1H, brs, H-15), 4.11 (2H, d, *J* = 3.5 Hz, H-14), 3.50 (3H, s, OCH~3~), 3.46 (3H, s, N-CH~3~), 2.68 (2H, m, Ar-CH~2~), 1.82 (3H, s, H~3~-18), 1.67 (3H, s, H~3~-17), 1.48 (6H, s, H~3~-12 and H~3~-13), 1.26 (3H, t, *J* = 7.5 Hz, CH~3~). ^13^C NMR: δ 182.3, 160.3, 158.0, 156.4, 153.8, 152.6, 149.6, 146.6, 145.6, 142.5, 138.5, 131.9, 129.1, 127.2, 127.2, 123.0, 123.0, 116.2, 115.6, 115.6, 110.4, 104.5, 104.0, 94.2, 78.1, 61.6, 38.4, 30.9, 28.4, 28.4, 26.4, 25.8, 18.2, 15.4. ESI-MS: 568 \[M -- H\]^−^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl(3-chlorophenyl)(methyl)carbamate (**AMG-10**) {#sec4.1.13}

^1^H NMR (CDCl~3~ 500 MHz): δ 13.52 (1H, *s*, 5-OH), 7.47 (1H, d, *J* = 1.5 Hz, Ar-H), 7.44--7.31 (2H, m, Ar-H), 7.28 (1H, s, H-1), 7.24 (1H, m, Ar-H), 6.73 (1H, *d*, *J* = 10.0 Hz, H-9), 6.26 (1H, s, H-8), 5.58 (1H, d, *J* = 10.0 Hz, H-10), 5.21 (1H, brs, H-15), 4.12 (2H, d, *J* = 5.5 Hz, H-14), 3.56 (3H, s, OCH~3~), 3.46 (3H, s, N-CH~3~), 1.83 (3H, s, H~3~-18), 1.68 (3H, s, H~3~-17), 1.48 (6H, s, H~3~-12 and H~3~-13). ^13^C NMR: δ 182.2, 160.3, 158.0, 156.4, 153.8, 152.4, 149.2, 146.7, 143.6, 138.7, 134.7, 134.7, 132.1, 130.2, 127.3, 123.1, 123.0, 116.5, 115.7, 115.6, 110.5, 104.5, 104.0, 94.2, 78.1, 61.7, 38.4, 28.4, 28.4, 26.3, 25.8, 18.2. ESI-MS *m*/*z*: 574 \[M -- H\]^−^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl(4-chlorophenyl)(methyl)carbamaten (**AMG-11**) {#sec4.1.14}

^1^H NMR (CDCl~3~ 500 MHz): δ 7.40 (2H, d, *J* = 8.5 Hz, Ar-H), 7.36 (2H, d, *J* = 8.5 Hz, Ar-H), 7.28 (1H, s, H-1), 6.73 (1H, *d*, *J* = 10.0 Hz, H-9), 6.26 (1H, s, H-8), 5.58 (1H, d, *J* = 10.0 Hz, H-10), 5.20 (1H, brs, H-15), 4.11 (2H, d, *J* = 5.5 Hz, H-14), 3.50 (3H, s, OCH~3~), 3.43 (3H, s, N-CH~3~), 1.83 (3H, s, H~3~-18), 1.68 (3H, s, H~3~-17), 1.48 (6H, s, H~3~-12 and H~3~-13). ^13^C NMR: δ 182.2, 160.2, 158.0, 156.4, 153.7, 152.1, 149.3, 146.6, 141.2, 138.4, 132.0, 129.4, 127.2, 123.1, 123.0, 116.2, 115.6, 115.5, 110.5, 104.8, 104.1, 94.2, 78.1, 61.4, 37.4, 28.4, 28.4, 26.3, 25.8, 18.2. ESI-MS *m*/*z*: 576 \[M + H\]^+^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl(2-bromophenyl)(methyl)carbamate (**AMG-12**) {#sec4.1.15}

^1^H NMR (CDCl~3~ 500 MHz): δ 13.54 (1H, *s*, 5-OH), 7.48--7.71 (1H, d, *J* = 8.0 Hz, Ar-H), 7.47--7.42 (2H, m, Ar-H), 7.32 (1H, s, H-1), 7.24 (1H, d, *J* = 7.5 Hz, Ar-H), 6.73 (1H, *d*, *J* = 10.0 Hz, H-9), 6.25 (1H, s, H-8), 5.58 (1H, d, *J* = 10.0 Hz, H-10), 5.17 (1H, t, *J* = 7.5 Hz, H-15), 4.10 (2H, d, *J* = 7.5 Hz, H-14), 3.50 (3H, s, OCH~3~), 3.37 (3H, s, N-CH~3~), 1.81 (3H, s, H~3~-18), 1.66 (3H, s, H~3~-17), 1.48 (6H, s, H~3~-12 and H~3~-13). ^13^C NMR: δ 182.2, 160.2, 158.0, 156.4, 153.7, 152.1, 149.3, 146.6, 141.2, 138.4, 133.6, 131.9, 129.7, 129.4, 128.7, 127.2, 123.1, 123.0, 116.3, 115.6, 110.3, 104.5, 104.0, 94.2, 78.1, 61.5, 38.6, 28.4, 28.4, 26.4, 25.8, 18.2. ESI-MS *m*/*z*: 620 \[M + H\]^+^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl(3-bromophenyl)(methyl)carbamate (**AMG-13**) {#sec4.1.16}

^1^H NMR (CDCl~3~ 500 MHz): δ 13.52 (1H, s, 5-OH), 7.46--7.60 (1H, d, *J* = 1.5 Hz, Ar-H), 7.45--7.24 (3H, m, Ar-H), 7.28 (1H, s, H-1), 6.73 (1H, *d*, *J* = 10.0 Hz, H-9), 6.26 (1H, s, H-8), 5.58 (1H, d, *J* = 10.0 Hz, H-10), 5.20 (1H, brs, H-15), 4.11 (2H, d, *J* = 4.0 Hz, H-14), 3.49 (3H, s, OCH~3~), 3.43 (3H, s, N-CH~3~), 1.83 (3H, s, H~3~-18), 1.68 (3H, s, H~3~-17), 1.48 (6H, s, H~3~-12 and H~3~-13). ^13^C NMR: δ 182.1, 160.3, 158.0, 156.4, 153.8, 152.2, 149.2, 146.7, 143.7, 138.6, 132.0, 130.5, 127.2, 127.2, 123.0, 123.0, 122.5, 116.3, 115.6, 115.6, 110.5, 104.6, 104.0, 94.2, 78.1, 61.7, 38.4, 28.4, 28.4, 26.4, 25.8, 18.2. ESI-MS *m*/*z*: 620 \[M + H\]^+^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl(4-bromophenyl)(methyl)carbamate (**AMG-14**) {#sec4.1.17}

^1^H NMR (CDCl~3~ 500 MHz): δ 13.52 (1H, s, 5-OH), 7.55 (2H, d, *J* = 8.5 Hz, Ar-H), 7.28 (1H, s, H-1), 7.23 (2H, d, *J* = 8.5 Hz, Ar-H), 6.73 (1H, *d*, *J* = 10.0 Hz, H-9), 6.26 (1H, s, H-8), 5.58 (1H, d, *J* = 10.0 Hz, H-10), 5.19 (1H, brs, H-15), 4.11 (2H, d, *J* = 4.0 Hz, H-14), 3.49 (3H, s, OCH~3~), 3.43 (3H, s, N-CH~3~), 1.83 (3H, s, H~3~-18), 1.68 (3H, s, H~3~-17), 1.48 (6H, s, H~3~-12 and H~3~-13). ^13^C NMR: δ 182.1, 160.3, 158.0, 156.4, 153.8, 152.2, 149.2, 146.7, 141.5, 138.6, 132.3, 132.0, 127.2, 123.0, 123.0, 116.3, 115.6, 115.6, 110.5, 104.5, 104.0, 94.2, 78.1, 61.7, 38.4, 28.4, 28.4, 26.3, 25.8, 18.2. ESI-MS *m*/*z*: 618 \[M -- H\]^−^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl(4-butylphenyl)(methyl)carbamate (**AMG-15**) {#sec4.1.18}

^1^H NMR (CDCl~3~ 500 MHz): δ 13.55 (1H, s, 5-OH), 7.29 (2H, d, *J* = 8.0 Hz, Ar-H), 7.28 (1H, s, H-1), 7.23 (2H, d, *J* = 8.0 Hz, Ar-H), 6.74 (1H, *d*, *J* = 10.0 Hz, H-9), 6.26 (1H, s, H-8), 5.58 (1H, d, *J* = 10.0 Hz, H-10), 5.19 (1H, brs, H-15), 4.11 (2H, d, *J* = 4.0 Hz, H-14), 3.45 (3H, s, OCH~3~), 3.41 (3H, s, N-CH~3~), 2.62 (2H, t, *J* = 7.0 Hz, Ar-CH~2~), 1.83 (3H, s, H~3~-18), 1.68 (3H, s, H~3~-17), 1.60 (2H, m, CH~2~), 1.48 (6H, s, H~3~-12 and H~3~-13), 1.37 (2H, m, CH~2~), 0.94 (3H, t, *J* = 7.0 Hz, CH~3~). ^13^C NMR: δ 182.3, 160.3, 158.0, 156.4, 153.8, 152.6, 149.6, 146.7, 140.1, 138.4, 131.9, 129.2, 127.2, 126.4, 123.1, 116.1, 115.8, 115.7, 110.4, 104.5, 104.0, 94.2, 78.1, 61.6, 38.6, 35.2, 33.5, 28.4, 28.4, 26.3, 25.8, 22.3, 18.2, 13.9. ESI-MS *m*/*z*: 596 \[M -- H\]^−^.

### 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2,6-dihydropyrano\[3,2-*b*\]xanthen-9-yl(3-ethoxyphenyl)(methyl)carbamate (**AMG-16**) {#sec4.1.19}

^1^H NMR (CDCl~3~ 500 MHz): δ 13.55 (1H, *s*, 5-OH), 7.31--7.28 (4H, m, Ar-H), 7.24 (1H, s, H-1), 6.74 (1H, *d*, *J* = 10.0 Hz, H-9), 6.26 (1H, s, H-8), 5.58 (1H, d, *J* = 10.0 Hz, H-10), 5.19 (1H, brs, H-15), 4.12 (2H, d, *J* = 4.0 Hz, H-14), 4.06 (2H, q, *J* = 7.5 Hz, OCH~2~CH~3~), 3.49 (3H, s, OCH~3~), 3.44 (3H, s, N-CH~3~), 1.83 (3H, s, H~3~-18), 1.68 (3H, s, H~3~-17), 1.48 (6H, s, H~3~-12 and H~3~-13), 1.26 (3H, t, *J* = 7.5 Hz, OCH~2~CH~3~). ^13^C NMR: δ 182.3, 160.2, 159.6, 158.0, 156.4, 153.8, 152.4, 149.5, 146.7, 143.8, 138.4, 131.9, 129.8, 127.3, 127.2, 123.1, 123.0, 116.3, 115.6, 113.2, 110.4, 104.5, 104.0, 94.2, 78.1, 61.6, 58.4, 38.6, 28.4, 28.4, 26.3, 25.8, 18.2, 14.7. ESI-MS *m*/*z*: 584 \[M -- H\]^−^.

*In Vitro* Experiments {#sec4.2}
----------------------

### Neuroprotective Effect Assay {#sec4.2.1}

PC12 cells (pheochromocytoma) were obtained from the Chinese Academy of Medical Sciences, Shanghai Institutes for Biological Sciences. Cells were grown in a culture flask at a humidified atmosphere of 5% CO~2~ and in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum supplemented with 100 U/mL penicillin/streptomycin at 37 °C. The culture medium was changed every 2 days. Cells were seeded in 96-well plates (3 × 10^4^ cells per well) 48 h prior to treatment. All compounds were dissolved in dimethyl sulfoxide (DMSO), with the final concentration of DMSO less than 0.1%. PC12 cells were pretreated with various concentrations of all compounds for 24 h and exposed to 300 μM H~2~O~2~ for an additional 12 h. The control cells were treated with an equal amount of DMEM. Edaravone was set as a positive drug. The cell viability was assessed by the MTT assay.^[@ref34]^

### AChE Inhibition Assay {#sec4.2.2}

AChE inhibitory activity was studied using Ellman's method with slight modifications.^[@ref35]^ Briefly, 220 μL of an assay mixture containing 50 μL of the sample solution, 140 μL of 100 mM phosphate buffer, 10 μL of 2.5 mM DTNB, and 20 μL of 1.0 U/mL AChE solution was added to each well of a 96-well plate. The microplate was incubated at 37 °C for 10 min, and then 40 μL of 7.5 mMAtCHI was added and incubated at 37 °C for 10 min. The absorbance of the mixture was determined at 412 nm using a microplate reader instrument (Multiskan MK3, Thermo Fisher).

### Cytotoxicity {#sec4.2.3}

The *in vitro* cytotoxicity of α-M, AMG, and 16 derivatives of AMG was evaluated by the MTT assay in PC12 cell lines with edaravone as a positive control. All compounds were prepared by dissolving in a certain amount of DMSO and diluted with culture medium to give a single concentration of 10 μM. PC12 cells were seeded in 96-well plates at a density of 10^5^/well and allowed to accommodate for 24 h in normal conditions. The cultures were then exposed to above compounds in concentrations of 10 μM for 24 h. After 24 h, the compound-treated cells were incubated for 2 h with 200 μL of MTT. Formazan was solubilized with 200 μL of DMSO, and the absorbance of each sample was read at 490 nm using a microplate reader instrument.^[@ref34]^

*In Vivo* Experiments {#sec4.3}
---------------------

### Animals {#sec4.3.1}

We used healthy ICR mice (18--22 g, half male and half female) for the acute toxicity assessment and adult Sprague--Dawley (SD) rats (8 weeks old, 280 ± 10 g) for the pharmacodynamic experiment of **AMG-1**. All animals were purchased from the Zhejiang Academy of Medical Sciences Laboratory Animal Center (license number: SCXK-20140001). All animals were housed and kept on a 12 h/12 h light/dark cycle in standard conditions with temperature and relative humidity set at 23 ± 2 °C and 55 ± 10%, respectively. All animals had free access to diet and water. Animal sacrifice at the end of the study was performed under deep anesthesia with 5% isoflurane, and then decapitation was performed. All experimental procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals in the Zhejiang University of Technology, Hangzhou, China, and conformed to the National Institutes of Health Guide for Care and Use of Laboratory Animals (Publication No. 85-23, revised 1996).

### Acute Oral Toxicity Study {#sec4.3.2}

The acute toxicity test of **AMG-1** was performed in healthy ICR mice.^[@ref36]^ The mice were randomly divided into seven groups (one control group and six treated groups) of 10 animals. **AMG-1** was suspended in 0.5% carboxymethyl cellulose solution, and the mice were exposed to a single dose of **AMG-1** 1310, 1638, 2048, 2560, 3200, and 4000 mg/kg body weight by the oral gavage, which were determined through respective pretesting. Control groups were administered a 0.5% carboxymethyl cellulose solution equally. Then, mice that survived were observed for 120 min and once daily for the next 14 day after the treatment. The general behavior, signs of toxicity, and mortality of the mice were assessed carefully. The number of survivors after the 14 day period was noted. The toxicological effect was evaluated based on the mortality for 14 day, which was expressed by the median lethal dose value (LD~50~) estimated from the regression of the log-probit mortality rate.

### Surgery and Drug Treatment {#sec4.3.3}

The experimental procedure for creating AD model rats was slightly modified from that in the previously reported study.^[@ref37]^ In brief, Aβ~25-35~ was first dissolved in sterile 0.9% saline at a concentration of 5 μg/μL and incubated at 37°C for 4 days to allow aggregation before the hippocampal injection. Rats were weighed and general anesthetized with 5% isoflurane and fixed into a stereotaxic apparatus. A burr hole was drilled through the skull above the bilateral hippocampal coordinates (anterior--posterior (AP) = −3.5 mm, medial--lateral (ML) = ±2.5 mm from the bregma, and dorsal--ventral (DV) = 3.0 mm from the skull surface) according to the stereotaxic atlas. Aβ~25-35~ (2 μL containing 10 μg) was subsequently injected over 5 min through a microsyringe into the hole. The needle was left for an additional 5 min before the withdrawal. Sham-vehicle rats underwent the same surgical procedure, except that normal saline (as a vehicle of Aβ~25-35~) was bilaterally injected. After 1 day of Aβ~25-35~ hippocampal injection, all operated rats were randomly divided into six groups (*n* = 20) and administered orally different drug treatments once daily for 30 days (for experimental schedules, see [Supporting Figure 1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c00057/suppl_file/ao0c00057_si_001.pdf)): sham control group (vehicle only), positive group (1 mg/kg donepezil), Aβ~25-35~-induced model group (vehicle only), Aβ~25-35~ + **AMG-1** 5 mg/kg group, Aβ~25-35~ + **AMG-1** 10 mg/kg group, and Aβ~25-35~ + **AMG-1** 20 mg/kg group.

### Open-Field Test for the Locomotor Ability {#sec4.3.4}

After **AMG-1** administration for 30 days, rats were subjected to an open-field test to evaluate the exploratory activity and locomotor ability.^[@ref38]^ The open-field apparatus was a clear cubic box with a Plexiglas floor, was 100 × 100 × 50 cm^3^ in size (BW-OF362, Shanghai, China), and was dimly illuminated during the test. After 1 h of acclimation in the dim room, each rat was placed in the same place of the open arena and allowed to freely explore for 2 min. The floor and walls were cleaned with 70% ethanol to eliminate the odor between each trial. The rats' behavior was recorded by a video digital recorder suspended 1.8 m above the area. The locomotor activity was analyzed by the total distance traveled (m).

### Morris Water Maze {#sec4.3.5}

The spatial learning and memory ability of all rats was tested by the Morris water maze (XR-XM101, Shanghai, China).^[@ref39]^ Briefly, a circular pool (180 cm in diameter and 60 cm in depth) was filled with water and maintained at 25 ± 1 °C. Animals were trained to seek an escape platform (25 cm^2^ Plexiglas square, 2 cm below the surface of the water in one of the four quadrants) with four trials for 2 min per trial with a 30 min interval between the trials, daily, for 5 consecutive days. On locating the platform, the rat was allowed to remain there for 30 s before being returned to its cage. If the rat did not find the platform within 2 min, the time was recorded as 2 min. The rat was then manually guided to the platform where it stayed for 30 s. The escape latency and swim pattern were measured by a video tracking system for the analysis of performance. After completion of the escape latency test, rats were subjected to a probe trial in which the platform was removed from the pool and replaced by a visible platform. Rats were placed in the pool at the same pole and allowed to swim for 2 min. The number of rats crossing the target quadrant was recorded.

### Tissue Preparation {#sec4.3.6}

On the terminal day, the rats were deeply anesthetized with 5% isoflurane. The whole brains of eight rats were isolated after performing intracardiac perfusion with 100 mmol/L phosphate-buffered saline (PBS). Then, the brains were quickly removed and the brain tissues were fixed in 10% neutral buffered formalin, dehydrated, and embedded in paraffin for coronal microtome sections with hematoxylin staining and Bielschowsky silver staining. Similarly, the whole brains of six rats perfused with PBS, followed by ice-cold 4% paraformaldehyde, were sectioned into 30 μm slices for immunohistochemical staining. The remaining brains of the rats were isolated and postfixed in 50 mmol/L PBS containing 4% paraformaldehyde overnight, immersed in a solution containing 30% sucrose in 50 mmol/L PBS, and stored at 4 °C until sectioning. The frozen brains were sectioned by a freezing microtome (Thermo Fisher) at 25 μm for Nissl staining.

### Hematoxylin and Eosin (HE) Staining {#sec4.3.7}

After animal behavior test experiments, four rats in each group were chosen randomly to be sacrificed. Their brains were quickly removed and fixed in 4% formalin. The brains were then dehydrated in alcohol and embedded in paraffin for coronal microtome sections (5 μm thick) with HE staining for histomorphological study under the light microscope (200×, Nikon, Japan).^[@ref40]^

### Nissl Staining {#sec4.3.8}

Hippocampi of brain tissues of six rats were cut into 25 μm thick sections by a freezing microtome (Thermo Fisher) and series stained using a Nissl staining solution (Beyotime Institute of Biotechnology, Nangtong, China) according to the manufacturer's instructions. In brief, the sections were mounted onto gelatin-coated slides. After being dipped in 98% EtOH for 2 min, slides were immersed in xylene for 2 min and rehydrated in a series of concentrations of EtOH from 98 to 70 to 50 to 20 to 0% (distilled water) for 2 min each. Sections were then stained with 2% cresyl violet for 5 min. After two dips in distilled water, sections were dehydrated with a series of concentrations of EtOH from 50 to 70 to 98% and then were cleaned in xylene and mounted with Permount. At the end of staining, the neuronal survival and loss of Nissl bodies in the hippocampus were observed using light microscopy (Nikon, Japan).^[@ref41]^

### Bielschowsky Silver Staining {#sec4.3.9}

Bielschowsky silver staining was used to assess the Aβ plaques and neurofibrillary tangles (NFTs), the hallmark lesions of AD. Representative tissue sections were stained by a modified Bielschowsky method.^[@ref42]^ Briefly, coronal brain sections (40 μm) were cut with the microtome, and the rehydrated sections were covered with 20% AgNO~3~ in the dark for 20 min, followed by rinsing in distilled water and incubation in the ammoniacal silver solution for 10 min in the dark. After the incubation, the slides were immersed in ammoniated water and developed. Finally, sections were rinsed, dehydrated, cleared, and coverslipped. Positive silver-stained neurons were counted and photographed under 10 × 40 magnification with light microscopy (Nikon, Japan).

### Immunohistochemistry Analysis for Aβ~1-42~ {#sec4.3.10}

Immunohistochemistry for Aβ~1-42~ was performed as described.^[@ref43]^ Briefly, hippocampal sections of five rats were deparaffinized in xylene and hydrated through graded alcohol. Endogenous peroxidase was blocked with 3% hydroxide in 10% methanol. Then, sections were incubated in blocking serum, 5% normal goat serum in 0.3% Triton with PBS. Subsequently, sections were incubated in a primary antibody anti-Aβ~1-42~ (rabbit anti-rat amyloid β protein 1-42 monoclonal antibody 1:300 dilution, Dakopatts A/C; Bioss China) solution overnight at 4 °C. Sections were washed in PBS with 0.3% Triton X-100 and incubated in a secondary antibody (biotinylated goat anti-rabbit antibody, 1:500) solution for 1 h at room temperature, which was followed by washing and staining with DAB (1:1000) for another 10 min at room temperature. Stained sections were mounted on resin-coated slides and dried. Photomicrographs of brain sections were taken using a digital camera (Nikon, Japan), and at least 20 fields from each brain section were analyzed using the Image J software.

### Chemogenomics Databases and Tools {#sec4.3.11}

Chemogenomics Database for Alzheimer's Disease (<http://www.cbligand.org/AD/>),^[@ref44]^ Chemogenomics Database for Drug Abuse Research (<http://www.cbligand.org/CDAR/>),^[@ref45]^ and Chemogenomics Database for Cardiovascular Disease (<http://www.cbligand.org/CVD/>)^[@ref46]^ were combined for the target prediction on α-mangostin and **AMG-1**. Two chemogenomics tools, TargetHunter^[@ref47]^ and HTDocking,^[@ref48]^ were used specifically for the identification of both therapeutic targets and off-target interactions. The inquiry compounds were α-mangostin (1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9*H*-xanthen-9-one) and **AMG-1** (5-hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-6-oxo-2*H*,6*H*-pyrano\[3,2-*b*\]xanthen-9-yl methyl(phenyl)carbamate). For TargetHunter, the fingerprint type was set to be extended-connectivity fingerprints 6 (ECFP6).^[@ref49],[@ref50]^ The threshold for 2D similarity was set to be 60%. For HTDocking, high-throughput molecular docking studies were performed between the inquired compounds and protein targets in each database. Networks were constructed using Cytoscape.^[@ref51]^ Both the *in silico* prediction and the reported experimental validations were combined. The layout format was set to the degree-sorted circle.

### Blood--Brain Barrier (BBB) Prediction, PAINS-Remover, and Toxtree {#sec4.3.12}

The BBB Prediction Server (<http://www.cbligand.org/BBB/>)^[@ref44],[@ref52]^ was used for the *in silico* evaluation of whether the inquired compounds can pass the BBB. For each compound, four fingerprint types, MACCS, Openbabel (FP2), Molprint 2D, and PubChem, were applied. For each fingerprint type, two algorithms, AdaBoost and SVM, were adapted. A total of eight combinations of fingerprints and algorithms were calculated for both α-mangostin and **AMG-1**.

PAINS-Remover (<http://www.cbligand.org/PAINS/>)^[@ref53]^ was used to detect and remove the pan-assay interference compounds (PAINS). Both α-mangostin and **AMG-1** were analyzed to identify the existence of the undesired substructural features.

Toxtree (<http://toxtree.sourceforge.net/index.html>)^[@ref54]^ was used to estimate any toxic hazard by applying a tree approach. The SMILES formats of α-mangostin and **AMG-1** functioned as the input. Three levels, low (Class I), intermediate (Class II), and high (Class III), of estimated toxic hazards were reported.

Statistical Analysis {#sec4.4}
--------------------

Data were analyzed using one-way ANOVA, followed by the least significant difference post-hoc tests or the independent samples *t*-tests. The results are expressed as mean ± SEM. Differences between groups were considered statistically significant when *P* \< 0.05. All statistical analyses were performed using the SPSS 19.0 software (SPSS Inc; 19.0).

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.0c00057](https://pubs.acs.org/doi/10.1021/acsomega.0c00057?goto=supporting-info).Animal study timeline (Figure S1); ^1^H and ^13^C NMR spectra of all of the reported synthesized compounds (Figures S2--S33) ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c00057/suppl_file/ao0c00057_si_001.pdf))
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